Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: A randomised, double-blind, crossover study (eXtRa)

Schizophrenia Research

Volumn 162, Issue 1-3, 2015, Pages 162-168

  Riedel, Michael ^a   Schmitz, Margot ^b   Østergaard, Peter Kåre ^c   Ferrannini, Luigi ^c   Franco, Manuel A ^d,e   Alfano, Vincenza ^c   Vansvik, Eva Dencker ^f  

^a Vinzenz von Paul Hospital   (Germany)

^b Department of Psychiatry   (Austria)

^c Private Practice ^*  (Italy)

^d Hospital General de Zamora   (Spain)

^e UNIVERSITY OF SALAMANCA   (Spain)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

Daytime cognitive function; Quetiapine extended release; Quetiapine immediate release; Stable schizophrenia; Treatment satisfaction

Indexed keywords

DRUG METABOLITE; NORQUETIAPINE; PLACEBO; QUETIAPINE; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTENTION; BOND LADER VISUAL ANALOG SCALE; COGNITION; COGNITION ASSESSMENT; COGSTATE COGNITION TESTING; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAYTIME SOMNOLENCE; DELUSION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; EXTENDED DRUG RELEASE; FATIGUE; FEMALE; HEART ARRHYTHMIA; HUMAN; IMMEDIATE DRUG RELEASE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STANFORD SLEEPINESS SCALE; STEADY STATE; TACHYCARDIA; TREATMENT DURATION; VERTIGO; VISUAL ANALOG SCALE; BLOOD; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG EFFECTS; EUROPE; NEUROPSYCHOLOGICAL TEST; PHOTOPERIODICITY; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; COGNITION; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PATIENT SATISFACTION; PHOTOPERIOD; PROSPECTIVE STUDIES; QUETIAPINE FUMARATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84923262008     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.12.027     Document Type: Article

References (17)

1. Chengappa K.N., Parepally H., Brar J.S., Mullen J., Shilling A., Goldstein J.M. A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Can. J. Psychiatry 2003, 48(3):187-194.
2. Datto C., Berggren L., Jitendra P., Eriksson H. Self-reported sedation profile of immediate release quetiapine fumarate compared with extended release quetiapine fumarate during dose initiation: a randomised, double-blind, cross-over study in healthy adult subjects. Clin. Ther. 2009, 31(3):492-502.
3. DiBonaventura M., Gabriel S., Dupclay L., Gupta S., Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012, 12(1):20.
4. Figueroa C., Brecher M., Hamer-Maansson J.E., Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(2):199-204.
5. Fleiss J. Sample size determination, design and analysis of clinical experiments 1999, 369. John Wiley and Sons, New York.
6. Jeste S., Patterson T., Palmer B., Dolder C., Goldman S., Jeste D. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr. Res. 2003, 63(1-2):49-58.
7. Kitchen H., Rofail D., Heron L., Sacco P. Cognitive impairment associated with schizophrenia: a review of the humanistic burden. Adv. Ther. 2012, 29(2):148-162.
8. Kivircik Akdede B., Alptekin K., Kitiş A., Arkar H., Akvardar Y. Effects of quetiapine on cognitive functions in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29(2):233-238.
9. Lacro J., Dunn L., Dolder C., Leckband S., Jeste D. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 2002, 63(10):892-909.
10. Loebel A.D., Siu C.O., Cucchiaro J.B., Pikalov A.A., Harvey P.D. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS Spectr. 2014, 19(2):197-205.
11. Maruff P., Thomas E., Cysique L., Brew B., Collie A., Snyder P., Pietrzak R. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch. Clin. Neuropsychol. 2009, 24(2):165-178.
12. Meulien D., Huizar K., Brecher M. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Hum. Psychopharmacol. 2010, 25(2):103-115.
13. Peuskens J. The management of schizophrenia: focus on extended-release quetiapine fumarate. Neuropsychiatr. Dis. Treat. 2011, 7:549-564.
14. Pietrzak R., Olver J., Norman T., Piskulic D., Maruff P., Snyder P. A comparison of the CogState schizophrenia battery and the measurement and treatment research to improve cognition in schizophrenia (MATRICS) battery in assessing cognitive impairment in chronic schizophrenia. J. Clin. Exp. Neuropsychol. 2009, 31(7):848-859.
15. Riedel M., Schennach-Wolff R., Musil R., Dehning S., Cerovecki A., Opgen-Rhein M., Matz J., Seemuller F., Obermeier M., Engel R.R., Muller N., Moller H.J., Spellmann I. Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum. Psychopharmacol. Clin. Exp. 2010, 25:116-125.
16. Riesenberg R., Baldytcheva I., Datto C. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study. Clin. Ther. 2012, 34(11):2202-2211.
17. Robinson D., Woerner M.G., Alvir J.M.J., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 1999, 56(3):241-247.